Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Jan;59(1):20–25. doi: 10.1136/ard.59.1.20

Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia

S Migliaresi 1, A Bresciani 1, L Ambrosone 1, M Spera 1, D Barbarulo 1, V Lombari 1, G Pirozzi 1, G Borgia 1, M L Lombardi 1, G Tirri 1, C Manzo 1
PMCID: PMC1752989  PMID: 10627422

Abstract

OBJECTIVE—To investigate whether quantitative alterations of both β2microglobulin (β2µ) associated HLA class I heavy chains (sHLA-I) and β2 µ free class I heavy chains (sHLA-FHC) in sera of patients with hepatitis C virus (HCV) infection occur and whether they distinguish patients with mixed cryoglobulinaemia (MC).
METHODS—83 HCV infected patients were studied and divided into three groups: (A) without cryoglobulinaemia (n=21), (B) with polyclonal MC (n=20), (C) with monoclonal MC (n=42). Serum sHLA-I and sHLA-FHC were measured by double determinant radioimmunoassay using monoclonal antibodies: TP25.99 as catching antibody, and NAMB-1 and HC-10 as revealing antibodies. Western blot identified HLA-I isoforms.
RESULTS—The serum concentrations of sHLA-I and of sHLA-FHC in HCV infected patients versus controls were respectively 1.3(0.5) µg/ml (mean (SD)) versus 0.8 (0.3) (p<0.001) and 13.9 (7.1) ng/ml versus 9.2 (5) (p<0.001). sHLA-I were 1.01 (0.4) µg/ml in group A, 1.04 (0.4) µg/ml in group B, and 1.47 (0.4) µg/ml in group C (p=0.001). Statistical analysis showed a significant difference versus controls for groups B (p<0.02) and C (p<0.001). sHLA-FHC were 12.8 (8.3) ng/ml in group A, 17.2 (7.1) ng/ml in group B, and 12.9 (6.2) ng/ml in group C (p<0.02). A significant difference versus controls for each group was found (p<0.02, p<0.001, and p<0.02, respectively). Different patterns of sHLA-I isoforms were observed.
CONCLUSIONS—Increased serum concentrations of sHLA-I and sHLA-FHC characterise HCV infected patients. The highest sHLA-I concentrations seem to distinguish patients with monoclonal MC. In this last condition sHLA could play a part in the HCV escape and in B cell proliferation. The significance of sHLA-FHC is still undefined.



Full Text

The Full Text of this article is available as a PDF (205.5 KB).

Figure 1  .

Figure 1  

Open in a new tab

Concentrations of sHLA-I and sHLA-FHC in serum of HCV infected patients and in controls. sHLA-FHC values are expressed in terms of ng/ml of bound 125I-mAb HC-10. Each dot indicates the value of sHLA-I (panel A) and of sHLA-FHC (panel B) in a serum sample. The bars indicate means (SD).

Figure 2  .

Figure 2  

Open in a new tab

Concentrations of sHLA-I and sHLA-FHC in the serum of HCV infected patients, divided by disease pattern, and in controls. sHLA-FHC values are expressed in terms of ng/ml of bound 125I-mAb HC-10. Each dot indicates the value of sHLA-I (panel A) and of sHLA-FHC (panel B) in a serum sample. The bars indicate means (SD).

Figure 3  .

Figure 3  

Open in a new tab

Relation between serum sHLA-I concentrations and cryocrit.

Figure 4  .

Figure 4  

Open in a new tab

Western blot analysis of sHLA-I and sHLA-FHC isolated from sera of HCV infected patients and controls. HLA-I were immunoprecipitated by anti β2-µ mAb NAMB-1 (panel A) from sera of HCV infected patients and controls. Lanes 1 to 3: patients with MC and CS; lanes 4-5: patients with MC without CS; lanes 6-7: patients without MC; lane 8: controls; lane 9: PBS. HLA-FHC were immunoprecipitated by anti-HLA-FHC mAB HC-10 (panel B) from sera of HCV infected patients and controls. Lanes 1-2: patients with MC and CS; lane 3: patient with MC without CS; lane 4: patient without MC; lane 5: controls; lane 6: PBS. After separation by SDS-PAGE, antigens were transferred to a nitrocellulose membrane and detected by 125I-mAb TP25.99. PBS was used as a negative control.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol. 1997;19(1):111–129. doi: 10.1007/BF00945029. [DOI] [PubMed] [Google Scholar]
  2. Alvarez-Cermeño J. C., Casado C., Villar L. M., Ferreira A., Varela J. M., Dominguez M., Bootello A., Najera R., Gonzalez-Porque P. Soluble class 1 antigens (sHLA) in CSF and serum of patients with HIV infection. Acta Neurol Scand. 1990 Jul;82(1):14–16. doi: 10.1111/j.1600-0404.1990.tb01580.x. [DOI] [PubMed] [Google Scholar]
  3. Alvarez-Cermeño J., Echevarría J. M., Villar L. M., Lázaro I., Bootello A., González-Porque P. Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis. J Neurol Neurosurg Psychiatry. 1989 Oct;52(10):1194–1196. doi: 10.1136/jnnp.52.10.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Arguedas O., Porras O., Fasth A. Juvenile chronic arthritis in Costa Rica. A pilot referral study. Clin Exp Rheumatol. 1995 Jan-Feb;13(1):119–123. [PubMed] [Google Scholar]
  5. Bresciani A., Pirozzi G., Spera M., Lombardi M. L., Ambrosone L., Migliaresi S., Ferrone S., Manzo C. Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens. 1998 Jul;52(1):44–50. doi: 10.1111/j.1399-0039.1998.tb03022.x. [DOI] [PubMed] [Google Scholar]
  6. Brieva J. A., Villar L. M., Leoro G., Alvarez-Cermeño J. C., Roldán E., Gonzalez-Porqué P. Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma. Clin Exp Immunol. 1990 Nov;82(2):390–395. doi: 10.1111/j.1365-2249.1990.tb05459.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brouet J. C., Clauvel J. P., Danon F., Klein M., Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974 Nov;57(5):775–788. doi: 10.1016/0002-9343(74)90852-3. [DOI] [PubMed] [Google Scholar]
  8. Carbone E., Terrazzano G., Colonna M., Tuosto L., Piccolella E., Franksson L., Palazzolo G., Pérez-Villar J. J., Fontana S., Kärre K. Natural killer clones recognize specific soluble HLA class I molecules. Eur J Immunol. 1996 Mar;26(3):683–689. doi: 10.1002/eji.1830260326. [DOI] [PubMed] [Google Scholar]
  9. Ferri C., Caracciolo F., Zignego A. L., La Civita L., Monti M., Longombardo G., Lombardini F., Greco F., Capochiani E., Mazzoni A. Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. Br J Haematol. 1994 Oct;88(2):392–394. doi: 10.1111/j.1365-2141.1994.tb05036.x. [DOI] [PubMed] [Google Scholar]
  10. Ferri C., Greco F., Longombardo G., Palla P., Moretti A., Marzo E., Fosella P. V., Pasero G., Bombardieri S. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum. 1991 Dec;34(12):1606–1610. doi: 10.1002/art.1780341221. [DOI] [PubMed] [Google Scholar]
  11. Gabrielli A., Manzin A., Candela M., Caniglia M. L., Paolucci S., Danieli M. G., Clementi M. Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clin Exp Immunol. 1994 Jul;97(1):87–93. doi: 10.1111/j.1365-2249.1994.tb06584.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gorevic P. D., Kassab H. J., Levo Y., Kohn R., Meltzer M., Prose P., Franklin E. C. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980 Aug;69(2):287–308. doi: 10.1016/0002-9343(80)90390-3. [DOI] [PubMed] [Google Scholar]
  13. Gumber S. C., Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995 Oct 15;123(8):615–620. doi: 10.7326/0003-4819-123-8-199510150-00008. [DOI] [PubMed] [Google Scholar]
  14. Hagihara M., Shimura T., Takebe K., Munkhbat B., Hosoi K., Kagawa T., Watanabe N., Matsuzaki S., Yamamoto K., Sato K. Serum concentrations of soluble HLA-class I and CD8 forms in patients with viral hepatic disorders. J Gastroenterol. 1997 Jun;32(3):338–343. doi: 10.1007/BF02934490. [DOI] [PubMed] [Google Scholar]
  15. Hausmann R., Zavazava N., Steinmann J., Müller-Ruchholtz W. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol. 1993 Jan;91(1):183–188. doi: 10.1111/j.1365-2249.1993.tb03376.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kao K. J., Scornik J. C., Riley W. J., McQueen C. F. Association between HLA phenotype and HLA concentration in plasma or platelets. Hum Immunol. 1988 Feb;21(2):115–124. doi: 10.1016/0198-8859(88)90086-9. [DOI] [PubMed] [Google Scholar]
  17. Martin P. Hepatitis C: more than just a liver disease. Gastroenterology. 1993 Jan;104(1):320–323. doi: 10.1016/0016-5085(93)90869-e. [DOI] [PubMed] [Google Scholar]
  18. McMurray R. W., Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum. 1997 Feb;26(4):689–701. doi: 10.1016/s0049-0172(97)80005-4. [DOI] [PubMed] [Google Scholar]
  19. Meltzer M., Franklin E. C. Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability. Am J Med. 1966 Jun;40(6):828–836. doi: 10.1016/0002-9343(66)90199-9. [DOI] [PubMed] [Google Scholar]
  20. Monteverde A., Ballarè M., Pileri S. Hepatic lymphoid aggregates in chronic hepatitis C and mixed cryoglobulinemia. Springer Semin Immunopathol. 1997;19(1):99–110. doi: 10.1007/BF00945028. [DOI] [PubMed] [Google Scholar]
  21. Monteverde A., Rivano M. T., Allegra G. C., Monteverde A. I., Zigrossi P., Baglioni P., Gobbi M., Falini B., Bordin G., Pileri S. Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections. Acta Haematol. 1988;79(1):20–25. doi: 10.1159/000205684. [DOI] [PubMed] [Google Scholar]
  22. Nocito M., Montalbán C., González-Porque P., Villar L. M. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol. 1997 Dec;58(2):106–111. doi: 10.1016/s0198-8859(97)00227-9. [DOI] [PubMed] [Google Scholar]
  23. Onji M., Kikuchi T., Kumon I., Masumoto T., Nadano S., Kajino K., Horiike N., Ohta Y. Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology. 1992 Aug;39(4):340–343. [PubMed] [Google Scholar]
  24. Pellegrino M. A., Ng A. K., Russo C., Ferrone S. Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation. 1982 Jul;34(1):18–23. doi: 10.1097/00007890-198207000-00004. [DOI] [PubMed] [Google Scholar]
  25. Pickl W. F., Majdic O., Faé I., Reuschel R., Holter W., Knapp W. The soluble pool of beta 2-microglobulin free HLA class I alpha-chains. Qualitative and quantitative characterization. J Immunol. 1993 Sep 1;151(5):2613–2622. [PubMed] [Google Scholar]
  26. Pozzato G., Mazzaro C., Crovatto M., Modolo M. L., Ceselli S., Mazzi G., Sulfaro S., Franzin F., Tulissi P., Moretti M. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994 Nov 1;84(9):3047–3053. [PubMed] [Google Scholar]
  27. Puppo F., Brenci S., Lanza L., Bosco O., Imro M. A., Scudeletti M., Indiveri F., Ferrone S. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum Immunol. 1994 Aug;40(4):259–266. doi: 10.1016/0198-8859(94)90025-6. [DOI] [PubMed] [Google Scholar]
  28. Puppo F., Indiveri F., Scudeletti M., Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today. 1997 Apr;18(4):154–155. doi: 10.1016/s0167-5699(97)84660-9. [DOI] [PubMed] [Google Scholar]
  29. Puppo F., Picciotto A., Brenci S., Varagona G., Scudeletti M., Ghio M., Balestra V., Celle G., Indiveri F. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? J Clin Immunol. 1995 Jul;15(4):179–184. doi: 10.1007/BF01541087. [DOI] [PubMed] [Google Scholar]
  30. Puppo F., Scudeletti M., Indiveri F., Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today. 1995 Mar;16(3):124–127. doi: 10.1016/0167-5699(95)80127-8. [DOI] [PubMed] [Google Scholar]
  31. Qian C., Camps J., Maluenda M. D., Civeira M. P., Prieto J. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J Hepatol. 1992 Nov;16(3):380–383. doi: 10.1016/s0168-8278(05)80674-9. [DOI] [PubMed] [Google Scholar]
  32. Sakaguchi K., Koide N., Takenami T., Matsushima H., Takabatake H., Ferrone S., Tsuji T. Soluble HLA class I antigens in sera of patients with chronic hepatitis. Gastroenterol Jpn. 1992 Apr;27(2):206–211. doi: 10.1007/BF02777724. [DOI] [PubMed] [Google Scholar]
  33. Stam N. J., Spits H., Ploegh H. L. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 1986 Oct 1;137(7):2299–2306. [PubMed] [Google Scholar]
  34. Zavazava N., Hausmann R., Müller-Ruchholtz W. Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA. Transplantation. 1991 Apr;51(4):838–842. doi: 10.1097/00007890-199104000-00019. [DOI] [PubMed] [Google Scholar]
  35. Zavazava N., Krönke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med. 1996 Sep;2(9):1005–1010. doi: 10.1038/nm0996-1005. [DOI] [PubMed] [Google Scholar]
  36. Zignego A. L., Ferri C., Giannini C., La Civita L., Careccia G., Longombardo G., Bellesi G., Caracciolo F., Thiers V., Gentilini P. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role. Arch Virol. 1997;142(3):545–555. doi: 10.1007/s007050050100. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES